The All-Regional Association Isotope (part of Rosatom) has begun preclinical trials of a radiopharmaceutical for targeted destruction of prostate cancer. It has been reported DEA News.
All-Regional Association Isotope has begun preclinical studies of a targeted radiopharmaceutical based on the thorium-227 isotope and antibodies for the treatment of prostate cancer.
The research will be held at Ulyanovsk State University and will last until 2024.
It is stated that thorium-227 is more effective in killing cancer cells.
Denis Altunin, formerly oncologist, specialist of the “SM-Clinic” Oncology Center saidIn the early stages, kidney cancer may not manifest itself at all and is discovered, as a rule, by chance when diagnosing another disease. He says that in the following periods, blood in the urine, pain in the back or sides that do not go away, sudden weight loss, weakness and fever.